GlassScriptPhysician profile
Rick W Gebhart
NPI 1306849823
$12,384.70
in general payments reported to CMS, 2019-2025
50 companies · $2,276 in 2025
The $2,276 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,086 · 2020: $1,321 · 2021: $1,748 · 2022: $1,743 · 2023: $2,016 · 2024: $2,195 · 2025: $2,276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,350 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,350.43 |
| Education | $136.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,949.20 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,414.06 | 2021-2025 | |
| Lilly USA, LLC | $1,060.80 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Otsuka America Pharmaceutical, INC. | $933.83 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Novo Nordisk INC | $752.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $749.31 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $394.85 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $384.35 | 2019-2025 | Trintellix |
| Pfizer INC. | $350.85 | 2021-2025 | |
| Axsome Therapeutics, INC. | $319.70 | 2023-2025 | Sunosi, Auvelity, Symbravo |
| Supernus Pharmaceuticals, INC. | $298.10 | 2021-2025 | Qelbree, Qelbree |
| Antares Pharma, INC. | $283.67 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $262.13 | 2019-2025 | Jardiance |
| Vivus LLC | $243.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $238.04 | 2020-2025 | Trelegy Ellipta |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Gebhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.